Decaborane

CAS RN:17702-41-9

Health Effects

0.2.1 SUMMARY OF EXPOSURE
  • 0.2.1.1 ACUTE EXPOSURE
    • A) Decaborane may cause primarily neurologic effects, including CNS depression and excitability, spasms, seizures, coma, and possibly permanent neuropsychological deficits. Liver and kidney damage may also occur. It is less toxic than pentaborane, whose effects it resembles, but is more toxic than diborane.
0.2.3 VITAL SIGNS
  • 0.2.3.1 ACUTE EXPOSURE
    • A) Cough, wheezing, tachypnea, mild hypertension, or fever may be noted after exposure to the boron hydrides, but decaborane is generally less active than diborane for effects on respiration.
0.2.4 HEENT
  • 0.2.4.1 ACUTE EXPOSURE
    • A) Headache has been noted after spills and low level exposures to decaborane. Borohydrides are irritants and have caused irreversible eye damage.
0.2.5 CARDIOVASCULAR
  • 0.2.5.1 ACUTE EXPOSURE
    • A) Arrhythmias and cardiac arrest have been seen in human poisonings with pentaborane. Hypertension, bradycardia and decreased cardiac output have been produced in dogs.
0.2.6 RESPIRATORY
  • 0.2.6.1 ACUTE EXPOSURE
    • A) Chest tightness, dyspnea, cough and wheezing may occur for 3 to 5 days after exposure. Pulmonary edema and pneumonia may also occur.
0.2.7 NEUROLOGIC
  • 0.2.7.1 ACUTE EXPOSURE
    • A) Dizziness, weakness, CNS depression and excitation, hallucinations, and incoordination have been seen. Mental deficits have been produced by acute exposures. Gross tremors, hypoglossal spasms, and unusual positioning of the hands have been seen in decaborane intoxication. Seizures have occurred in experimental animals. Pentaborane is more active for neurological effects than diborane.
  • 0.2.7.2 CHRONIC EXPOSURE
    • A) Headache, dizziness, vertigo, fatigue, chills, and weakness may occur. Apathy, stupor, pain insensitivity, confusion, amnesia and difficulty concentrating may also occur.
0.2.8 GASTROINTESTINAL
  • 0.2.8.1 ACUTE EXPOSURE
    • A) Nausea is one of the first symptoms seen.
0.2.9 HEPATIC
  • 0.2.9.1 ACUTE EXPOSURE
    • A) Fatty degeneration of the liver may occur. Liver function tests may be abnormal.
  • 0.2.9.2 CHRONIC EXPOSURE
    • A) Pathologic changes were seen in the livers of experimental animals exposed to decaborane by inhalation.
0.2.10 GENITOURINARY
  • 0.2.10.1 ACUTE EXPOSURE
    • A) Kidney damage may occur.
  • 0.2.10.2 CHRONIC EXPOSURE
    • A) Pathologic changes were seen in the tubules of experimental animals exposed to decaborane by inhalation.
0.2.11 ACID-BASE
  • 0.2.11.1 ACUTE EXPOSURE
    • A) Profound metabolic acidosis without respiratory compensation may occur.
0.2.13 HEMATOLOGIC
  • 0.2.13.1 ACUTE EXPOSURE
    • A) Leukocytosis may appear after 24 to 48 hours.
  • 0.2.13.2 CHRONIC EXPOSURE
    • A) Decreased leukocytes and hematocrit were seen in rats exposed to decaborane for six months.
0.2.14 DERMATOLOGIC
  • 0.2.14.1 ACUTE EXPOSURE
    • A) Dermatologic effects have not been reported for decaborane in humans. The other boron hydrides are irritants, however.
0.2.15 MUSCULOSKELETAL
  • 0.2.15.1 ACUTE EXPOSURE
    • A) Muscle pain may follow exposure. Tremors, diffuse fasciculations and muscle spasms have all been reported with severe decaborane or pentaborane intoxication. Gross tremors, hypoglossal spasms, and unusual positioning of the hands have been seen in decaborane intoxication. CPK values may be elevated.
0.2.17 METABOLISM
  • 0.2.17.1 ACUTE EXPOSURE
    • A) Decaborane inhibits various decarboxylases, including L-amino acid decarboxylase and histidine decarboxylase. This has the effect of depressing levels of serotonin, norepinephrine, and histamine.
0.2.18 PSYCHIATRIC
  • 0.2.18.1 ACUTE EXPOSURE
    • A) Post-traumatic stress disorder has been reported in persons exposed to pentaborane.
0.2.20 REPRODUCTIVE HAZARDS
  • A) No data were found for possible effects on teratogenesis, pregnancy, or lactation.
0.2.21 CARCINOGENICITY
  • 0.2.21.1 IARC CATEGORY
    • A) IARC Carcinogenicity Ratings for CAS17702-41-9 (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004):
      • 1) Not Listed
  • 0.2.21.2 HUMAN OVERVIEW
    • A) No carcinogenic studies were found.
0.2.22 GENOTOXICITY
  • A) No genetic data were available.
0.2.23 OTHER
  • 0.2.23.1 ACUTE EXPOSURE
    • A) Decaborane may be toxic by the inhalation, dermal, or oral route. The toxic species may be a polar intermediate formed in water which inhibits pyridoxal-containing enzymes.
Find more information on this substance at: Hazardous Substances Data Bank , TOXNET , PubMed